See more : KOIKE-YA Inc. (2226.T) Income Statement Analysis – Financial Results
Complete financial analysis of Kirin Holdings Company, Limited (KNBWY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kirin Holdings Company, Limited, a leading company in the Beverages – Alcoholic industry within the Consumer Defensive sector.
You may be interested
- Pernod Ricard SA (PER.DE) Income Statement Analysis – Financial Results
- REC Silicon ASA (0FS8.L) Income Statement Analysis – Financial Results
- YFY Inc. (1907.TW) Income Statement Analysis – Financial Results
- Motorpoint Group Plc (MOTR.L) Income Statement Analysis – Financial Results
- Austevoll Seafood ASA (ASTVF) Income Statement Analysis – Financial Results
Kirin Holdings Company, Limited (KNBWY)
About Kirin Holdings Company, Limited
Kirin Holdings Company, Limited produces and sells alcoholic beverages, soft drinks, pharmaceuticals, and other related products in Japan and internationally. It operates through four segments: Japan Beer and Spirits Businesses, Japan Non-Alcoholic Beverages Business, Oceania Integrated Beverages Business, and Pharmaceuticals Business. The company's products include beer, happo-shu, wine, whiskey, spirits, soft drinks, dairy products, fruit juices, and other products. It also produces and sells pharmaceutical products, biochemical products, and other products. In addition, the company engages in the factories and theme park businesses; management and operation of a chain of Kirin City beer pubs; and manufacture and sale of amino acids and nucleic acids for pharmaceutical and industrial use bulk pharmaceuticals, as well as margarine, jams, and honey. Further, it is involved in the manufacture and sale of Coca-Cola products and other soft drinks, and sake and other food products; as well as manufacture and supply of Four Roses bourbon; and acts as an insurance agent. The company was formerly known as Kirin Brewery Company, Limited and changed its name to Kirin Holdings Company, Limited in July 2007. Kirin Holdings Company, Limited was founded in 1885 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,134.39B | 1,989.47B | 1,821.57B | 1,849.55B | 1,941.31B | 1,930.52B | 1,863.73B | 2,075.07B | 2,196.93B | 2,195.80B | 2,254.59B | 2,186.18B | 2,071.77B | 2,177.80B | 2,278.47B | 1,922.88B | 1,400.61B | 1,263.63B | 1,634.76B | 1,205.09B | 1,166.94B | 1,126.68B | 1,098.10B | 1,071.90B | 906.01B | 881.24B | 869.59B | 881.70B | 892.50B | 921.12B | 1,574.81B | 1,603.21B | 1,531.64B | 754.06B |
| Cost of Revenue | 1,170.93B | 1,083.76B | 998.73B | 1,045.66B | 1,093.74B | 1,097.15B | 1,051.20B | 1,157.69B | 1,228.85B | 1,252.32B | 1,287.59B | 1,274.47B | 1,218.85B | 1,314.81B | 1,383.82B | 1,012.20B | 1,078.61B | 585.53B | 975.47B | 568.21B | 555.79B | 549.08B | 537.41B | 512.76B | 395.22B | 406.86B | 410.95B | 399.98B | 410.30B | 442.93B | 425.75B | 433.12B | 411.69B | 382.95B |
| Gross Profit | 963.47B | 905.71B | 822.84B | 803.88B | 847.56B | 833.37B | 812.53B | 917.38B | 968.07B | 943.48B | 967.00B | 911.71B | 852.92B | 862.99B | 894.65B | 910.67B | 321.99B | 678.09B | 659.29B | 636.88B | 611.16B | 577.60B | 560.69B | 559.14B | 510.79B | 474.38B | 458.64B | 481.72B | 482.20B | 478.19B | 1,149.06B | 1,170.09B | 1,119.96B | 371.11B |
| Gross Profit Ratio | 45.14% | 45.53% | 45.17% | 43.46% | 43.66% | 43.17% | 43.60% | 44.21% | 44.06% | 42.97% | 42.89% | 41.70% | 41.17% | 39.63% | 39.27% | 47.36% | 22.99% | 53.66% | 40.33% | 52.85% | 52.37% | 51.27% | 51.06% | 52.16% | 56.38% | 53.83% | 52.74% | 54.64% | 54.03% | 51.91% | 72.97% | 72.98% | 73.12% | 49.21% |
| Research & Development | 84.90B | 81.37B | 84.41B | 78.92B | 77.57B | 66.21B | 64.08B | 63.75B | 61.34B | 57.12B | 54.12B | 55.08B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.75B | 26.37B | 22.56B | 0.00 | 0.00 | 20.77B | 19.58B | 20.23B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 412.94B | 714.55B | 657.41B | 641.77B | 656.81B | 634.04B | 618.22B | 618.22B | 371.68B | 391.50B | 399.61B | 370.17B | 0.00 | 0.00 | 0.00 | 764.70B | 601.94B | 561.74B | 0.00 | 414.74B | 401.19B | 386.07B | 485.79B | 464.86B | 358.07B | 329.92B | 310.67B | 345.05B | 324.85B | 305.37B | 292.43B | 293.57B | 278.51B | 249.75B |
| Selling & Marketing | 221.47B | 225.41B | 222.43B | 150.29B | 159.26B | 155.66B | 158.21B | 155.80B | 385.46B | 364.14B | 357.81B | 317.97B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 62.21B | 56.62B | 56.10B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 634.40B | 714.55B | 657.41B | 641.77B | 656.81B | 634.04B | 618.22B | 618.22B | 757.14B | 755.64B | 757.42B | 688.13B | 0.00 | 0.00 | 0.00 | 764.70B | 601.94B | 561.74B | 0.00 | 476.95B | 457.81B | 442.17B | 485.79B | 464.86B | 358.07B | 329.92B | 310.67B | 345.05B | 324.85B | 305.37B | 292.43B | 293.57B | 278.51B | 249.75B |
| Other Expenses | 42.67B | 75.14B | 97.35B | 59.20B | 103.03B | 1.01B | -16.75B | -1.73B | 3.67B | -5.30B | -1.34B | 1.77B | 445.00M | 5.61B | 5.41B | 42.74B | 7.81B | -4.80B | -2.72B | -10.22B | -17.64B | -7.73B | -26.83B | -4.52B | 54.82B | -3.11B | 63.93B | -5.57B | -7.72B | -8.45B | -10.17B | -12.74B | -26.95B | -32.32B |
| Operating Expenses | 761.97B | 789.69B | 754.76B | 700.96B | 759.84B | 635.05B | 601.47B | 775.49B | 843.32B | 828.93B | 824.18B | 758.68B | 710.06B | 711.38B | 766.22B | 764.70B | 601.94B | 561.74B | -2.72B | 528.27B | 500.85B | 488.65B | 485.79B | 464.86B | 433.65B | 405.68B | 394.83B | 406.95B | 388.22B | 364.36B | 1,061.44B | 1,072.50B | 1,032.22B | 286.93B |
| Cost & Expenses | 1,932.90B | 1,873.45B | 1,753.49B | 1,746.63B | 1,853.58B | 1,732.20B | 1,652.66B | 1,933.18B | 2,072.17B | 2,081.25B | 2,111.77B | 2,033.15B | 1,928.91B | 2,026.19B | 2,150.04B | 1,776.90B | 1,680.56B | 1,147.27B | 975.47B | 1,096.49B | 1,056.64B | 1,037.73B | 1,023.20B | 977.62B | 828.87B | 812.54B | 805.78B | 806.93B | 798.52B | 807.29B | 1,487.19B | 1,505.62B | 1,443.91B | 669.89B |
| Interest Income | 9.04B | 10.98B | 4.09B | 5.40B | 4.82B | 9.18B | 4.83B | 2.67B | 2.78B | 3.88B | 4.43B | 3.82B | 3.88B | 1.22B | 2.57B | 2.40B | 1.97B | 1.48B | 1.06B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 10.52B | 6.48B | 7.04B | 8.52B | 9.45B | 8.88B | 11.08B | 13.25B | 20.07B | 24.38B | 21.35B | 22.83B | 20.92B | 22.05B | 19.62B | 25.39B | 12.62B | 9.74B | 9.21B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 87.23B | 85.94B | 81.13B | 82.11B | 80.74B | 67.95B | 69.23B | 71.62B | 121.93B | 148.60B | 149.04B | 146.36B | 142.76B | 139.99B | 127.50B | 95.95B | 79.36B | 68.43B | 537.75B | 76.17B | 81.28B | 77.51B | 76.29B | 75.24B | 54.82B | 56.18B | 63.93B | 61.91B | 63.37B | 58.99B | 57.35B | 50.86B | 45.09B | 37.18B |
| EBITDA | 294.80B | 251.27B | 227.59B | 215.18B | 207.01B | 250.96B | 254.75B | 251.14B | 230.66B | 263.15B | 291.85B | 302.78B | 300.49B | 303.00B | 239.73B | 256.16B | 212.94B | 152.19B | 659.29B | 184.90B | 191.58B | 166.46B | 151.18B | 169.52B | 131.95B | 124.88B | 127.74B | 136.67B | 157.35B | 172.82B | 144.97B | 148.45B | 132.82B | 121.35B |
| EBITDA Ratio | 13.81% | 11.85% | 10.31% | 11.63% | 10.66% | 15.74% | 16.72% | 12.39% | 12.30% | 12.17% | 13.42% | 14.07% | 14.50% | 13.91% | 12.80% | 13.32% | -15.14% | 12.04% | 39.74% | 14.93% | 17.47% | 15.62% | 13.12% | 17.55% | 16.02% | 14.86% | 14.68% | 14.98% | 16.41% | 17.28% | 8.15% | 8.19% | 6.23% | 9.69% |
| Operating Income | 201.50B | 116.02B | 106.66B | 102.92B | 126.27B | 198.32B | 211.07B | 141.89B | 124.75B | 114.55B | 142.82B | 153.02B | 142.87B | 151.61B | 128.44B | 145.98B | 120.61B | 116.36B | 111.85B | 107.71B | 101.66B | 88.95B | 74.89B | 94.28B | 77.14B | 68.70B | 63.81B | 74.76B | 93.99B | 113.83B | 87.62B | 97.59B | 87.74B | 84.17B |
| Operating Income Ratio | 9.44% | 5.83% | 5.86% | 5.56% | 6.50% | 10.27% | 11.32% | 6.84% | 5.68% | 5.22% | 6.33% | 7.00% | 6.90% | 6.96% | 5.64% | 7.59% | 8.61% | 9.21% | 6.84% | 8.94% | 8.71% | 7.89% | 6.82% | 8.80% | 8.51% | 7.80% | 7.34% | 8.48% | 10.53% | 12.36% | 5.56% | 6.09% | 5.73% | 11.16% |
| Total Other Income/Expenses | -4.45B | 227.00M | -65.81B | 21.63B | 29.10B | 48.53B | 22.64B | -15.83B | -107.33B | -36.67B | 14.39B | -19.43B | -57.95B | -71.29B | -35.82B | 19.76B | 7.81B | -4.80B | -2.72B | 616.25M | -30.05B | -20.84B | -22.39B | -24.63B | -9.75B | -10.33B | -5.60B | -2.95B | 1.71B | 4.61B | 6.21B | 9.58B | 14.50B | 19.55B |
| Income Before Tax | 197.05B | 191.39B | 99.62B | 124.55B | 116.82B | 246.85B | 233.78B | 180.76B | 17.42B | 77.88B | 157.21B | 133.59B | 84.92B | 80.33B | 92.61B | 165.74B | 128.41B | 111.56B | 109.13B | 108.32B | 71.61B | 68.11B | 52.51B | 69.65B | 67.38B | 58.37B | 58.21B | 71.82B | 95.70B | 118.44B | 93.83B | 107.18B | 102.24B | 103.73B |
| Income Before Tax Ratio | 9.23% | 9.62% | 5.47% | 6.73% | 6.02% | 12.79% | 12.54% | 8.71% | 0.79% | 3.55% | 6.97% | 6.11% | 4.10% | 3.69% | 4.06% | 8.62% | 9.17% | 8.83% | 6.68% | 8.99% | 6.14% | 6.05% | 4.78% | 6.50% | 7.44% | 6.62% | 6.69% | 8.15% | 10.72% | 12.86% | 5.96% | 6.69% | 6.68% | 13.76% |
| Income Tax Expense | 46.61B | 47.62B | 31.19B | 24.71B | 35.39B | 51.64B | 51.95B | 47.10B | 45.91B | 33.02B | 53.26B | 60.13B | 61.67B | 57.82B | 28.91B | 68.39B | 50.34B | 50.86B | 49.02B | 52.44B | 39.18B | 35.88B | 29.43B | 36.77B | 34.18B | 31.72B | 32.68B | 37.45B | 55.55B | 66.26B | 50.89B | 59.39B | 59.09B | 61.51B |
| Net Income | 112.70B | 111.01B | 59.79B | 99.84B | 81.44B | 164.20B | 241.99B | 118.16B | -47.33B | 32.39B | 85.66B | 56.20B | 7.41B | 11.39B | 49.17B | 80.18B | 66.71B | 53.51B | 51.38B | 48.33B | 32.43B | 32.24B | 23.07B | 32.88B | 33.20B | 26.65B | 25.53B | 34.37B | 40.15B | 52.18B | 42.93B | 47.79B | 43.15B | 42.22B |
| Net Income Ratio | 5.28% | 5.58% | 3.28% | 5.40% | 4.20% | 8.51% | 12.98% | 5.69% | -2.15% | 1.48% | 3.80% | 2.57% | 0.36% | 0.52% | 2.16% | 4.17% | 4.76% | 4.23% | 3.14% | 4.01% | 2.78% | 2.86% | 2.10% | 3.07% | 3.66% | 3.02% | 2.94% | 3.90% | 4.50% | 5.67% | 2.73% | 2.98% | 2.82% | 5.60% |
| EPS | 139.15 | 135.09 | 71.73 | 118.76 | 92.86 | 183.57 | 265.17 | 129.48 | -51.87 | 35.27 | 90.76 | 58.44 | 7.70 | 11.95 | 51.54 | 84.01 | 69.86 | 35.06 | 53.27 | 50.65 | 33.24 | 32.07 | 22.38 | 32.09 | 32.72 | 25.06 | 24.85 | 32.49 | 38.17 | 49.57 | 40.18 | 45.05 | 38.35 | 32.43 |
| EPS Diluted | 139.16 | 135.07 | 71.70 | 118.76 | 92.86 | 183.57 | 265.14 | 129.48 | -51.87 | 35.24 | 90.73 | 57.31 | 7.14 | 11.93 | 51.54 | 84.01 | 57.16 | 55.98 | 53.27 | 50.65 | 33.24 | 32.07 | 22.38 | 32.09 | 32.72 | 25.06 | 24.85 | 32.49 | 38.17 | 49.57 | 40.18 | 45.05 | 38.35 | 32.43 |
| Weighted Avg Shares Out | 809.90M | 821.76M | 833.60M | 840.69M | 877.04M | 894.51M | 912.58M | 912.52M | 912.45M | 918.52M | 943.73M | 961.67M | 961.81M | 953.90M | 954.06M | 954.47M | 954.95M | 984.51M | 964.55M | 954.20M | 966.09M | 984.51M | 984.51M | 1.00B | 1.00B | 1.06B | 1.03B | 1.05B | 1.05B | 1.05B | 1.07B | 1.06B | 1.13B | 1.30B |
| Weighted Avg Shares Out (Dil) | 809.85M | 821.76M | 833.60M | 840.69M | 877.04M | 894.51M | 912.58M | 912.52M | 912.54M | 919.18M | 944.08M | 980.60M | 1.04B | 955.07M | 954.06M | 954.47M | 954.95M | 984.51M | 1.10B | 966.08M | 966.09M | 984.51M | 984.51M | 1.00B | 1.00B | 1.06B | 1.03B | 1.05B | 1.05B | 1.05B | 1.07B | 1.06B | 1.13B | 1.30B |
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit...
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors –
Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company
TOKYO--(BUSINESS WIRE)--Japan-based Global Specialty Pharmaceutical Company Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto.) (TOKYO:4151) today announced that Masashi Miyamoto, Ph.D. will take the role of Chairman and CEO, after serving as President for the past 7 years. Abdul...
Kirin Holdings: More Patience Is Required
My Hold rating for Kirin Holdings is unchanged due to the company's mixed progress relating to diversification beyond the core beverages business, with the pharmaceuticals business growing well and Kyowa Hakko Bio struggling. Kyowa Hakko Bio's revenue decreased by -3%...
Kyowa Kirin Announces Positive Interim Real-world Data for Mogamulizumab (Poteligeo®) in Cutaneous T-cell Lymphoma at EORTC-CLTG 2024
GALASHIELS & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced it will present interim findings from three real-world studies in cutaneous T-cell lymphoma (CTCL) at the annual meeting...
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis
Rocatinlimab Met Co-Primary Endpoints of vIGA-ADTM 0/1 with a ≥ 2-Point Reduction from Baseline, EASI-75, and All Key Secondary Endpoints HORIZON is the First of Eight Phase 3 Trials in the ROCKET Program TOKYO , Sept. 25, 2024 /PRNewswire/ --...
Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting
One oral presentation and nine posters will shed light on real-world experiences of people living with XLH and the impact of burosumab treatment TOKYO , Sept. 19, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd.
KNBWY or DEO: Which Is the Better Value Stock Right Now?
Investors interested in Beverages - Alcohol stocks are likely familiar with Kirin Holdings Co. (KNBWY) and Diageo (DEO). But which of these two stocks is more attractive to value investors?
Kyowa Kirin to end distribution of Fareston (toremefine) in the United States
PRINCETON, N.J., Aug. 23, 2024 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd.
Source: https://incomestatements.info
Category: Stock Reports